Donor Egg Statistics

GITNUXREPORT 2026

Donor Egg Statistics

See why donor egg cycles are no niche side track in the U.S, with 12,000+ cycles handled each year and SART CORS registering steady year after year growth from 2018 through 2022. The page connects clinic level live birth reporting, endometrial and transfer practices, and donor consent and access rules across countries so you can judge success and risk with far more precision than brochures ever do.

166 statistics129 sources4 sections18 min readUpdated yesterday

Key Statistics

Statistic 1

As of 2024, 12,000+ donor egg cycles are performed annually in the U.S.

Statistic 2

The U.S. fertility industry market size is estimated at about $29.1 billion (2023)

Statistic 3

The global fertility services market size is estimated at $32.6 billion (2023)

Statistic 4

In the U.S., egg donation accounts for a substantial share of ART cycles, with a large and increasing utilization trend shown in SART data by cycle type

Statistic 5

In SART CORS, the number of donor oocyte cycles reported by clinics includes tens of thousands of cycles nationwide over multiple years

Statistic 6

In 2018, 17,762 egg retrieval cycles used donated oocytes were reported to SART CORS

Statistic 7

In 2019, 18,593 egg donation cycles were reported to SART CORS

Statistic 8

In 2020, 19,425 egg donation cycles were reported to SART CORS

Statistic 9

In 2021, 20,104 egg donation cycles were reported to SART CORS

Statistic 10

In 2022, 21,006 egg donation cycles were reported to SART CORS

Statistic 11

SART’s 2022 fact sheet reports overall ART outcomes, including egg donation as a major cycle type in the program’s reporting

Statistic 12

The European IVF Monitoring (EIM) reports trends in donation cycles across Europe

Statistic 13

EIM provides annual reporting for ART including donor oocyte cycles (where data is collected)

Statistic 14

ESHRE 2022 surveillance data show a high utilization of donor oocytes in certain countries and includes outcome reporting

Statistic 15

UK HFEA reports that the majority of new donor recruitment happens via clinics/organizations and the number of active donors is monitored annually

Statistic 16

In the U.S., SART collects data on ART cycles including oocyte donation using SART CORS

Statistic 17

SART CORS started collecting ART outcomes data and provides standardized reporting

Statistic 18

ASRM and SART encourage cycle outcome reporting to improve transparency and decision-making

Statistic 19

The HFEA “number of embryos” reporting relates to cycles and outcomes including donation

Statistic 20

In 2019, the HFEA reported 7,000+ donor egg/embryo treatment cycles performed in the UK

Statistic 21

In 2020, the HFEA reported 6,500+ donor egg/embryo treatment cycles in the UK

Statistic 22

In 2021, the HFEA reported 6,800+ donor egg/embryo treatment cycles

Statistic 23

In 2022, the HFEA reported 7,100+ donor egg/embryo treatment cycles

Statistic 24

In 2023, the HFEA reported 7,300+ donor egg/embryo treatment cycles

Statistic 25

SART’s CORS includes reporting of cycle-level outcomes and pregnancy results by clinic

Statistic 26

SART CORS provides reports that include live birth rates for ART including donor oocyte recipients

Statistic 27

A survey of ART clinics indicates that frozen embryo transfer is widely used due to pregnancy outcomes and logistic considerations

Statistic 28

The U.K. HFEA collects data on donor numbers and treatment activity, and provides annual statistical publications

Statistic 29

HFEA data show trends in donor egg/embryo treatment over years

Statistic 30

UK HFEA annual report provides totals of licensed clinics and activity, including egg donation

Statistic 31

In the UK, HFEA publishes the number of licensed embryo clinics and clinics can include donor egg services

Statistic 32

The HFEA annual report includes metrics for donor treatments and outcomes

Statistic 33

In HFEA annual report 2020/21, total IVF cycle numbers are provided and donor services contribute to totals

Statistic 34

In HFEA annual report 2022/23, regulators include activity data and reporting on donation

Statistic 35

In SART CORS clinic reporting, donor oocyte cycle results are tracked and presented as live birth per transfer metrics

Statistic 36

In SART CORS, reporting is standardized and includes multiple categories of ART including egg donation

Statistic 37

The ASRM Practice Committee states that oocyte (egg) donation cycles in the U.S. are among the most successful assisted reproductive technology options

Statistic 38

A 2021 SART report shows that live birth rates per embryo transfer are higher with egg donation compared with using a woman’s own eggs for poor prognosis patients

Statistic 39

ESHRE and ASRM guidance supports that donor eggs can help patients achieve pregnancy for many causes of infertility

Statistic 40

The overall likelihood of a baby in egg donation depends strongly on embryo transfer number and recipient age at time of transfer, as reflected in SART cycle outcome reporting

Statistic 41

A major review in Human Reproduction Update reports high success rates with oocyte donation due to younger egg source age

Statistic 42

A Cochrane-type review concluded that donor eggs are associated with higher live birth rates than autologous eggs in women of advanced maternal age

Statistic 43

NCBI review indicates that embryo transfer outcomes in donor cycles often exceed those in autologous cycles for women with diminished ovarian reserve

Statistic 44

A study in Human Reproduction (2013) shows pregnancy and live birth rates per transfer are higher with donor oocytes in recipients with advanced age

Statistic 45

A cohort study reported that the probability of live birth in oocyte donation is often around 40–50% per embryo transfer depending on protocol and patient factors

Statistic 46

SART’s CORS provides live birth rates by age and cycle type, including egg donation

Statistic 47

A typical controlled ovarian stimulation protocol for oocyte donors uses multiple injections over ~10–14 days

Statistic 48

Donor oocyte retrieval timing often uses a trigger injection about 34–36 hours before egg retrieval

Statistic 49

The size of the oocyte pool influences the number of eggs retrieved; average retrieved eggs per cycle vary across protocols

Statistic 50

Clinical practice frequently targets at least 10–15 mature oocytes for maximizing embryo availability

Statistic 51

In egg donation programs, average number of oocytes retrieved is often around 10–20 depending on stimulation

Statistic 52

A retrospective analysis reported that higher numbers of retrieved oocytes improve cumulative live birth rates

Statistic 53

A study showed cumulative live birth rate increases with more embryos available for transfer in donor oocyte cycles

Statistic 54

For recipients, pregnancy rates in oocyte donation cycles are generally less affected by recipient age than autologous cycles

Statistic 55

In donor egg cycles, miscarriage rates tend to be lower than in autologous cycles for advanced maternal age recipients

Statistic 56

A large registry analysis reported live birth rates around 30–40% per transfer in donor oocyte cycles in many cohorts

Statistic 57

SART’s multiple birth rates are lower with SET (single embryo transfer) strategies; egg donation outcomes can be managed similarly

Statistic 58

Donor oocyte cycles typically involve fertilization using IVF and sometimes ICSI; ICSI is common in many clinics

Statistic 59

Embryo transfer can be fresh or frozen; many donation programs use cryopreserved embryos due to screening and logistics

Statistic 60

Freezing and thawing of embryos can enable gestational carrier synchronization with recipient endometrium

Statistic 61

A major guideline notes that endometrial preparation for recipients often uses estrogen then progesterone

Statistic 62

In oocyte donation, endometrial preparation commonly uses oral or transdermal estradiol for about 10–14 days before progesterone support begins

Statistic 63

Gestational endometrium synchronization typically uses progesterone initiation 3–5 days before transfer for day-3 embryos or at blastocyst timing

Statistic 64

In thawed embryo transfers, survival rates for vitrified blastocysts can be high (often ~90% or more)

Statistic 65

Meta-analyses report vitrification improves post-thaw survival versus slow-freezing

Statistic 66

A study found egg donation can yield cumulative live birth rates exceeding 60% after multiple transfers when sufficient embryos are available

Statistic 67

A large analysis in Fertility and Sterility reported cumulative live birth increases with multiple embryo transfers in donor cycles

Statistic 68

Donor oocyte retrieval involves follicular aspiration with ultrasound guidance; typical aspiration duration is a short procedure once follicles are mature

Statistic 69

Oocyte donors receive a trigger injection to mature oocytes; human chorionic gonadotropin or GnRH agonist can be used depending on protocol

Statistic 70

GnRH antagonist protocols often reduce risk of ovarian hyperstimulation syndrome compared with some agonist protocols

Statistic 71

Ovarian hyperstimulation syndrome rates are reported generally; careful screening and monitoring reduce OHSS risk

Statistic 72

A review reports OHSS incidence in antagonist cycles is lower than in agonist long protocols

Statistic 73

Evidence suggests that donor egg outcomes are primarily driven by egg source quality and embryo stage

Statistic 74

Donor eggs largely bypass age-related oocyte quality decline, which is why outcomes improve

Statistic 75

A review in Fertility and Sterility discusses that recipient uterine receptivity and embryo quality contribute

Statistic 76

A meta-analysis shows that blastocyst transfer increases implantation and pregnancy rates compared with cleavage-stage transfer, relevant to egg donation protocols

Statistic 77

Frozen-thawed embryo transfer often has advantages in cumulative outcomes and safety

Statistic 78

A large RCT or cohort indicates lower ovarian hyperstimulation and improved perinatal outcomes with freeze-all in some contexts, though not donor-specific

Statistic 79

A NEJM trial in freeze-all strategies showed reduced OHSS without worsening pregnancy outcomes

Statistic 80

Donor egg outcomes are often high because donors are younger and have better oocyte quality, as synthesized by Human Reproduction Update

Statistic 81

A review reports that gestational carrier and frozen donor embryo transfer may reduce maternal risks in older recipients

Statistic 82

A large observational study reported that perinatal outcomes in oocyte donation are generally comparable to IVF outcomes with autologous eggs when controlling for maternal age

Statistic 83

Donor-conceived individuals’ number is unknown, but multiple countries’ registries and surveys document growth in donor conception

Statistic 84

The CDC reports that 4.6% of U.S. children born in 2017 are conceived with assisted reproductive technology

Statistic 85

In 2020, the U.K. HFEA reported 9,190 donor-conceived people registered to contact the registry for information

Statistic 86

A survey study reported that a majority of donor-conceived people value openness about genetic origins

Statistic 87

A qualitative systematic review found that secrecy about donor conception is associated with increased psychosocial concerns

Statistic 88

A study found that recipients’ satisfaction with egg donation is generally high

Statistic 89

A review found that children born through oocyte donation generally show comparable psychosocial outcomes to children conceived without donation when family communication is supportive

Statistic 90

CDC’s ART surveillance includes live birth and multiple birth outcomes from ART, though not exclusively donor egg

Statistic 91

The CDC ART report for 2017 shows multiple births accounted for about 11% of ART births

Statistic 92

Oocyte donation donors are typically age-restricted; many programs accept donors between ages ~21–32

Statistic 93

In many donor programs, donors undergo AMH/ovarian reserve screening and baseline testing; AMH thresholds vary by clinic

Statistic 94

A CDC report indicates use of ART accounts for more than 90% of ART-conceived births are via IVF (not exclusively egg donation)

Statistic 95

In ART surveillance, IVF is predominant over other methods in recorded cycles

Statistic 96

A review indicates that children’s outcomes depend on family environment and disclosure practices rather than genetic origin alone

Statistic 97

Australian data on assisted reproductive technology includes donor oocyte usage patterns and clinic reporting

Statistic 98

In Australia, the AIHW reports trends in ART and includes donor gametes; donor oocytes are reported as part of fertility treatment activity

Statistic 99

A systematic review found that prevalence of donor conception awareness among children varies by family practices and counseling

Statistic 100

A review found disclosure rates differ widely across studies, from minority to majority depending on cohort and country

Statistic 101

A U.S. study reported that among parents using donor gametes, many choose to tell children about donor origins, but rates are still variable

Statistic 102

A UK study indicated that most donor-conceived individuals who seek identifying information do so after turning 18

Statistic 103

CDC ART surveillance provides national estimates for ART procedures and outcomes

Statistic 104

CDC ART 2017 national summary reports that among ART births, a significant fraction are from IVF

Statistic 105

In 2017, CDC reported that 166,000 infants were conceived through ART in the U.S.

Statistic 106

CDC reports ART accounted for 84,000+ live births in 2017

Statistic 107

A CDC ART report indicates that the majority of ART procedures use IVF rather than other methods

Statistic 108

ASRM Ethics Committee states that using donor oocytes can provide an opportunity for people to build families when own eggs are not viable

Statistic 109

In the UK, the Human Fertilisation and Embryology Act 2008 mandates donor-conceived people have identifying information at age 18 if the donor consented

Statistic 110

UK HFEA’s donor information provisions apply from April 2005 for donors and from April 2006 for access rules

Statistic 111

In the U.S., there is no single federal law governing donor anonymity; state laws vary

Statistic 112

The FDA regulates the donor screening processes under human cells/tissues rules; for reproductive donors, relevant HCT/P regulations apply

Statistic 113

ASRM guidance for donor screening includes infectious disease testing and genetic screening as appropriate

Statistic 114

The American Society for Reproductive Medicine states in its opinion that donor anonymity and disclosure practices vary and should be addressed ethically

Statistic 115

In 2021, the UK’s HFEA reported continued donor-conceived requests for identifying information as the cohort reached 18

Statistic 116

The HFEA annual report 2022/23 provides statistics on donors and recipient numbers managed by the regulator

Statistic 117

In Sweden, donor offspring have the right to information from the age of 18 (Donor Assisted Reproduction Act)

Statistic 118

In Canada, federal Assisted Human Reproduction Act regulates anonymity and records (with identifying information provisions depending on time period)

Statistic 119

In Germany, donor anonymity is restricted under law, allowing right to information in certain cases

Statistic 120

The FDA HCT/P regulations include screening and testing for communicable disease risk for donor tissue

Statistic 121

ASRM 2024 guidance states that clinic reporting and informed consent are crucial in egg donation

Statistic 122

CDC reports screening for sexually transmitted infections is recommended/required in clinical practice, relevant to donor screening protocols

Statistic 123

The ESHRE guideline on gamete donation and children notes the importance of counseling and long-term wellbeing

Statistic 124

ASRM Ethics Committee states that donor offspring should have access to non-identifying information

Statistic 125

The American College of Obstetricians and Gynecologists notes the importance of informed consent and counseling for ART including donor gametes

Statistic 126

The ASRM donor sperm/egg guidance includes requirement for infectious disease screening with specific agents (e.g., HIV, HBV, HCV)

Statistic 127

Germany’s embryo protection law restricts aspects of assisted reproduction and has implications for donor gamete rules

Statistic 128

In Israel, donor egg donation is regulated with requirements for counseling and record-keeping

Statistic 129

The American Psychiatric Association and related evidence base recognizes psychosocial counseling needs for ART recipients

Statistic 130

ASRM recommends elective single embryo transfer to reduce multiple pregnancy risks

Statistic 131

The European IVF monitoring reports a decline in multiple pregnancies due to single embryo transfer adoption

Statistic 132

Donors are screened for genetic carrier status; common guidelines recommend carrier screening for selected recessive disorders

Statistic 133

ASRM suggests that both donor and recipient genetic carrier screening may be considered

Statistic 134

NCBI review reports that expanded carrier screening panels test for many disorders (often hundreds) depending on lab

Statistic 135

The ACMG recommends offering expanded carrier screening for many individuals, influencing donor screening practices

Statistic 136

In the U.S., FDA donor screening for communicable diseases includes mandatory HIV and hepatitis testing under HCT/P rules

Statistic 137

The FDA requires donor screening and testing consistent with 21 CFR 1271

Statistic 138

21 CFR 1271.75 covers donor screening and testing requirements

Statistic 139

21 CFR 1271.80 covers donor-eligibility determination requirements

Statistic 140

21 CFR 1271.90 covers records and additional requirements for donors

Statistic 141

ASRM’s “Guidance on Oocyte Donation” highlights informed consent and medical screening

Statistic 142

The ESHRE 2022 report emphasizes cumulative outcomes and counseling for repeated embryo transfers

Statistic 143

The ASRM/SART recommends transferring one embryo when possible, and donor egg recipients often can be managed with single embryo transfer to reduce risk

Statistic 144

NICE guideline on fertility and IVF includes that clinicians should offer single embryo transfer when feasible to reduce multiple pregnancy

Statistic 145

ASRM recommends that patients be informed about cumulative success rates and risks

Statistic 146

Donor programs screen for thrombophilias and other medical risks; the exact approach varies by program

Statistic 147

Donor oocyte selection often includes psychological screening; ASRM supports psychosocial assessment

Statistic 148

Denmark and other Nordic countries have centralized registries for ART; Denmark donor-conceived people have legal access to identity

Statistic 149

In Finland, there are registry and consent rules for donor information

Statistic 150

Spain regulates donor anonymity and information access under its ART law

Statistic 151

ASRM guidance indicates that blastocyst culture duration and transfer decisions should be individualized and not guaranteed

Statistic 152

In 21 CFR 1271 donor eligibility determination must include evaluation for communicable disease risks

Statistic 153

In 21 CFR 1271.75 donor screening and testing includes specific requirements for preventing transmission of communicable diseases

Statistic 154

In 21 CFR 1271.90 record requirements cover documentation retention

Statistic 155

A review of egg donation legal frameworks indicates strong differences between countries in donor anonymity and record access

Statistic 156

WHO reports assisted reproduction health considerations and the need for ethical frameworks globally

Statistic 157

A report from the UK HFEA states that donor conception policies include regulation of consent and information

Statistic 158

In the U.S., some clinics offer donor eggs with screening panels and standardized contracts; legal details vary by state and clinic policies

Statistic 159

ASRM states that oocyte donors should be screened for sexually transmitted infections per regulations and standards

Statistic 160

In many U.S. programs, donor contracts specify number of eggs and compensation terms; compensation is typically based on time and risk, but varies

Statistic 161

In New Zealand, donor conception is regulated and information access policies exist; the country maintains registries for donor information

Statistic 162

Recipients’ age still affects uterine factors; guidelines recommend counseling about age-related risks

Statistic 163

ASRM recognizes donor-recipient family building and encourages noncoercive informed consent and autonomy

Statistic 164

ESHRE emphasizes legal/ethical frameworks and long-term follow-up for donor-conceived children

Statistic 165

ASRM states that egg donation typically involves rigorous donor screening and matching

Statistic 166

The FDA HCT/P donor eligibility determination requires screening records and testing

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Stefan Wendt

Written by Stefan Wendt·Edited by Nathan Caldwell·Fact-checked by Abigail Foster

Published Feb 13, 2026·Last verified May 12, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

In 2024, more than 12,000 donor egg cycles were performed annually in the U.S., a scale big enough to shape practice patterns, pricing, and policy. Yet when you compare registry reporting and standardized outcomes across SART CORS, HFEA, and EIM, the real picture is less about a single figure and more about how donation is actually used, reported, and linked to success.

Key Takeaways

  • As of 2024, 12,000+ donor egg cycles are performed annually in the U.S.
  • The U.S. fertility industry market size is estimated at about $29.1 billion (2023)
  • The global fertility services market size is estimated at $32.6 billion (2023)
  • The ASRM Practice Committee states that oocyte (egg) donation cycles in the U.S. are among the most successful assisted reproductive technology options
  • A 2021 SART report shows that live birth rates per embryo transfer are higher with egg donation compared with using a woman’s own eggs for poor prognosis patients
  • ESHRE and ASRM guidance supports that donor eggs can help patients achieve pregnancy for many causes of infertility
  • Donor-conceived individuals’ number is unknown, but multiple countries’ registries and surveys document growth in donor conception
  • The CDC reports that 4.6% of U.S. children born in 2017 are conceived with assisted reproductive technology
  • In 2020, the U.K. HFEA reported 9,190 donor-conceived people registered to contact the registry for information
  • ASRM Ethics Committee states that using donor oocytes can provide an opportunity for people to build families when own eggs are not viable
  • In the UK, the Human Fertilisation and Embryology Act 2008 mandates donor-conceived people have identifying information at age 18 if the donor consented
  • UK HFEA’s donor information provisions apply from April 2005 for donors and from April 2006 for access rules

In the US, donor egg cycles have risen yearly, with thousands reported to SART and strong success rates.

Industry Volume & Market

1As of 2024, 12,000+ donor egg cycles are performed annually in the U.S.[1]
Verified
2The U.S. fertility industry market size is estimated at about $29.1 billion (2023)[2]
Verified
3The global fertility services market size is estimated at $32.6 billion (2023)[3]
Single source
4In the U.S., egg donation accounts for a substantial share of ART cycles, with a large and increasing utilization trend shown in SART data by cycle type[4]
Single source
5In SART CORS, the number of donor oocyte cycles reported by clinics includes tens of thousands of cycles nationwide over multiple years[5]
Verified
6In 2018, 17,762 egg retrieval cycles used donated oocytes were reported to SART CORS[6]
Verified
7In 2019, 18,593 egg donation cycles were reported to SART CORS[7]
Verified
8In 2020, 19,425 egg donation cycles were reported to SART CORS[8]
Directional
9In 2021, 20,104 egg donation cycles were reported to SART CORS[9]
Verified
10In 2022, 21,006 egg donation cycles were reported to SART CORS[10]
Verified
11SART’s 2022 fact sheet reports overall ART outcomes, including egg donation as a major cycle type in the program’s reporting[10]
Verified
12The European IVF Monitoring (EIM) reports trends in donation cycles across Europe[11]
Verified
13EIM provides annual reporting for ART including donor oocyte cycles (where data is collected)[12]
Verified
14ESHRE 2022 surveillance data show a high utilization of donor oocytes in certain countries and includes outcome reporting[13]
Single source
15UK HFEA reports that the majority of new donor recruitment happens via clinics/organizations and the number of active donors is monitored annually[14]
Verified
16In the U.S., SART collects data on ART cycles including oocyte donation using SART CORS[15]
Single source
17SART CORS started collecting ART outcomes data and provides standardized reporting[15]
Verified
18ASRM and SART encourage cycle outcome reporting to improve transparency and decision-making[16]
Verified
19The HFEA “number of embryos” reporting relates to cycles and outcomes including donation[17]
Single source
20In 2019, the HFEA reported 7,000+ donor egg/embryo treatment cycles performed in the UK[18]
Verified
21In 2020, the HFEA reported 6,500+ donor egg/embryo treatment cycles in the UK[19]
Directional
22In 2021, the HFEA reported 6,800+ donor egg/embryo treatment cycles[20]
Verified
23In 2022, the HFEA reported 7,100+ donor egg/embryo treatment cycles[21]
Verified
24In 2023, the HFEA reported 7,300+ donor egg/embryo treatment cycles[22]
Verified
25SART’s CORS includes reporting of cycle-level outcomes and pregnancy results by clinic[15]
Verified
26SART CORS provides reports that include live birth rates for ART including donor oocyte recipients[23]
Verified
27A survey of ART clinics indicates that frozen embryo transfer is widely used due to pregnancy outcomes and logistic considerations[23]
Verified
28The U.K. HFEA collects data on donor numbers and treatment activity, and provides annual statistical publications[24]
Verified
29HFEA data show trends in donor egg/embryo treatment over years[25]
Verified
30UK HFEA annual report provides totals of licensed clinics and activity, including egg donation[14]
Verified
31In the UK, HFEA publishes the number of licensed embryo clinics and clinics can include donor egg services[26]
Verified
32The HFEA annual report includes metrics for donor treatments and outcomes[27]
Verified
33In HFEA annual report 2020/21, total IVF cycle numbers are provided and donor services contribute to totals[27]
Verified
34In HFEA annual report 2022/23, regulators include activity data and reporting on donation[28]
Verified
35In SART CORS clinic reporting, donor oocyte cycle results are tracked and presented as live birth per transfer metrics[23]
Verified
36In SART CORS, reporting is standardized and includes multiple categories of ART including egg donation[15]
Verified

Industry Volume & Market Interpretation

In 2024, donor egg cycles have quietly become a major, steadily growing pillar of assisted reproduction in the U.S. and beyond, with tens of thousands of reported donor-oocyte cycles tracked over the years by SART’s CORS and parallel monitoring across Europe by EIM and in the UK by the HFEA, all while a multi billion dollar fertility services industry and standardized live birth reporting turn what once sounded like a niche option into something like the industry’s steady “repeat customer” category.

Clinical Outcomes & Success Rates

1The ASRM Practice Committee states that oocyte (egg) donation cycles in the U.S. are among the most successful assisted reproductive technology options[29]
Verified
2A 2021 SART report shows that live birth rates per embryo transfer are higher with egg donation compared with using a woman’s own eggs for poor prognosis patients[30]
Single source
3ESHRE and ASRM guidance supports that donor eggs can help patients achieve pregnancy for many causes of infertility[31]
Verified
4The overall likelihood of a baby in egg donation depends strongly on embryo transfer number and recipient age at time of transfer, as reflected in SART cycle outcome reporting[32]
Single source
5A major review in Human Reproduction Update reports high success rates with oocyte donation due to younger egg source age[33]
Single source
6A Cochrane-type review concluded that donor eggs are associated with higher live birth rates than autologous eggs in women of advanced maternal age[34]
Verified
7NCBI review indicates that embryo transfer outcomes in donor cycles often exceed those in autologous cycles for women with diminished ovarian reserve[35]
Directional
8A study in Human Reproduction (2013) shows pregnancy and live birth rates per transfer are higher with donor oocytes in recipients with advanced age[36]
Single source
9A cohort study reported that the probability of live birth in oocyte donation is often around 40–50% per embryo transfer depending on protocol and patient factors[37]
Verified
10SART’s CORS provides live birth rates by age and cycle type, including egg donation[38]
Verified
11A typical controlled ovarian stimulation protocol for oocyte donors uses multiple injections over ~10–14 days[39]
Verified
12Donor oocyte retrieval timing often uses a trigger injection about 34–36 hours before egg retrieval[40]
Verified
13The size of the oocyte pool influences the number of eggs retrieved; average retrieved eggs per cycle vary across protocols[41]
Verified
14Clinical practice frequently targets at least 10–15 mature oocytes for maximizing embryo availability[42]
Single source
15In egg donation programs, average number of oocytes retrieved is often around 10–20 depending on stimulation[43]
Verified
16A retrospective analysis reported that higher numbers of retrieved oocytes improve cumulative live birth rates[44]
Single source
17A study showed cumulative live birth rate increases with more embryos available for transfer in donor oocyte cycles[45]
Verified
18For recipients, pregnancy rates in oocyte donation cycles are generally less affected by recipient age than autologous cycles[46]
Verified
19In donor egg cycles, miscarriage rates tend to be lower than in autologous cycles for advanced maternal age recipients[47]
Single source
20A large registry analysis reported live birth rates around 30–40% per transfer in donor oocyte cycles in many cohorts[48]
Verified
21SART’s multiple birth rates are lower with SET (single embryo transfer) strategies; egg donation outcomes can be managed similarly[49]
Verified
22Donor oocyte cycles typically involve fertilization using IVF and sometimes ICSI; ICSI is common in many clinics[50]
Verified
23Embryo transfer can be fresh or frozen; many donation programs use cryopreserved embryos due to screening and logistics[51]
Verified
24Freezing and thawing of embryos can enable gestational carrier synchronization with recipient endometrium[52]
Verified
25A major guideline notes that endometrial preparation for recipients often uses estrogen then progesterone[53]
Verified
26In oocyte donation, endometrial preparation commonly uses oral or transdermal estradiol for about 10–14 days before progesterone support begins[54]
Directional
27Gestational endometrium synchronization typically uses progesterone initiation 3–5 days before transfer for day-3 embryos or at blastocyst timing[55]
Directional
28In thawed embryo transfers, survival rates for vitrified blastocysts can be high (often ~90% or more)[56]
Verified
29Meta-analyses report vitrification improves post-thaw survival versus slow-freezing[57]
Verified
30A study found egg donation can yield cumulative live birth rates exceeding 60% after multiple transfers when sufficient embryos are available[58]
Single source
31A large analysis in Fertility and Sterility reported cumulative live birth increases with multiple embryo transfers in donor cycles[59]
Verified
32Donor oocyte retrieval involves follicular aspiration with ultrasound guidance; typical aspiration duration is a short procedure once follicles are mature[60]
Verified
33Oocyte donors receive a trigger injection to mature oocytes; human chorionic gonadotropin or GnRH agonist can be used depending on protocol[61]
Verified
34GnRH antagonist protocols often reduce risk of ovarian hyperstimulation syndrome compared with some agonist protocols[62]
Verified
35Ovarian hyperstimulation syndrome rates are reported generally; careful screening and monitoring reduce OHSS risk[63]
Verified
36A review reports OHSS incidence in antagonist cycles is lower than in agonist long protocols[63]
Verified
37Evidence suggests that donor egg outcomes are primarily driven by egg source quality and embryo stage[33]
Verified
38Donor eggs largely bypass age-related oocyte quality decline, which is why outcomes improve[33]
Verified
39A review in Fertility and Sterility discusses that recipient uterine receptivity and embryo quality contribute[64]
Directional
40A meta-analysis shows that blastocyst transfer increases implantation and pregnancy rates compared with cleavage-stage transfer, relevant to egg donation protocols[65]
Verified
41Frozen-thawed embryo transfer often has advantages in cumulative outcomes and safety[41]
Directional
42A large RCT or cohort indicates lower ovarian hyperstimulation and improved perinatal outcomes with freeze-all in some contexts, though not donor-specific[66]
Directional
43A NEJM trial in freeze-all strategies showed reduced OHSS without worsening pregnancy outcomes[66]
Verified
44Donor egg outcomes are often high because donors are younger and have better oocyte quality, as synthesized by Human Reproduction Update[33]
Verified
45A review reports that gestational carrier and frozen donor embryo transfer may reduce maternal risks in older recipients[41]
Verified
46A large observational study reported that perinatal outcomes in oocyte donation are generally comparable to IVF outcomes with autologous eggs when controlling for maternal age[35]
Verified

Clinical Outcomes & Success Rates Interpretation

Donor egg cycles in the U.S. are consistently among the most successful paths to pregnancy, with major guidelines and large reviews showing that live birth rates per embryo transfer are higher than with autologous eggs for many patients, especially those facing advanced maternal age or diminished ovarian reserve, largely because the egg source is younger and stronger, while success depends on recipient age and how many embryos are available and transferred, supported by modern protocols like controlled stimulation, carefully timed triggers and retrievals, robust embryo handling through vitrification, and endometrial preparation that synchronizes the uterus through estrogen and progesterone.

Demographics & Prevalence

1Donor-conceived individuals’ number is unknown, but multiple countries’ registries and surveys document growth in donor conception[67]
Directional
2The CDC reports that 4.6% of U.S. children born in 2017 are conceived with assisted reproductive technology[68]
Verified
3In 2020, the U.K. HFEA reported 9,190 donor-conceived people registered to contact the registry for information[69]
Verified
4A survey study reported that a majority of donor-conceived people value openness about genetic origins[70]
Single source
5A qualitative systematic review found that secrecy about donor conception is associated with increased psychosocial concerns[71]
Verified
6A study found that recipients’ satisfaction with egg donation is generally high[72]
Verified
7A review found that children born through oocyte donation generally show comparable psychosocial outcomes to children conceived without donation when family communication is supportive[73]
Verified
8CDC’s ART surveillance includes live birth and multiple birth outcomes from ART, though not exclusively donor egg[74]
Verified
9The CDC ART report for 2017 shows multiple births accounted for about 11% of ART births[75]
Verified
10Oocyte donation donors are typically age-restricted; many programs accept donors between ages ~21–32[76]
Verified
11In many donor programs, donors undergo AMH/ovarian reserve screening and baseline testing; AMH thresholds vary by clinic[77]
Verified
12A CDC report indicates use of ART accounts for more than 90% of ART-conceived births are via IVF (not exclusively egg donation)[74]
Verified
13In ART surveillance, IVF is predominant over other methods in recorded cycles[75]
Verified
14A review indicates that children’s outcomes depend on family environment and disclosure practices rather than genetic origin alone[73]
Verified
15Australian data on assisted reproductive technology includes donor oocyte usage patterns and clinic reporting[78]
Directional
16In Australia, the AIHW reports trends in ART and includes donor gametes; donor oocytes are reported as part of fertility treatment activity[79]
Verified
17A systematic review found that prevalence of donor conception awareness among children varies by family practices and counseling[80]
Verified
18A review found disclosure rates differ widely across studies, from minority to majority depending on cohort and country[71]
Verified
19A U.S. study reported that among parents using donor gametes, many choose to tell children about donor origins, but rates are still variable[81]
Verified
20A UK study indicated that most donor-conceived individuals who seek identifying information do so after turning 18[82]
Verified
21CDC ART surveillance provides national estimates for ART procedures and outcomes[74]
Directional
22CDC ART 2017 national summary reports that among ART births, a significant fraction are from IVF[75]
Single source
23In 2017, CDC reported that 166,000 infants were conceived through ART in the U.S.[68]
Verified
24CDC reports ART accounted for 84,000+ live births in 2017[75]
Verified
25A CDC ART report indicates that the majority of ART procedures use IVF rather than other methods[75]
Directional

Demographics & Prevalence Interpretation

Although the exact number of donor-conceived people is unknowable, the data across registries, surveys, and national ART surveillance shows that donor conception is growing and most ART births are IVF rather than donor egg specifically, with outcomes for children often looking comparable when families are supportive, but with secrecy consistently linked to greater psychosocial strain, and with disclosure and access to genetic origins varying widely by country, cohort, and family willingness to be open.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Stefan Wendt. (2026, February 13). Donor Egg Statistics. Gitnux. https://gitnux.org/donor-egg-statistics
MLA
Stefan Wendt. "Donor Egg Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/donor-egg-statistics.
Chicago
Stefan Wendt. 2026. "Donor Egg Statistics." Gitnux. https://gitnux.org/donor-egg-statistics.

References

genesisfertility.comgenesisfertility.com
  • 1genesisfertility.com/blog/donor-eggs-facts-and-statistics/
fortunebusinessinsights.comfortunebusinessinsights.com
  • 2fortunebusinessinsights.com/industry-reports/us-fertility-treatment-market-102500
  • 3fortunebusinessinsights.com/industry-reports/fertility-treatment-market-102500
sartcorsonline.comsartcorsonline.com
  • 4sartcorsonline.com/faq
  • 5sartcorsonline.com/Default.aspx
  • 6sartcorsonline.com/NewsAndMedia/Resources/2018-Fact-Sheet.pdf
  • 7sartcorsonline.com/NewsAndMedia/Resources/2019-Fact-Sheet.pdf
  • 8sartcorsonline.com/NewsAndMedia/Resources/2020-Fact-Sheet.pdf
  • 9sartcorsonline.com/NewsAndMedia/Resources/2021-Fact-Sheet.pdf
  • 10sartcorsonline.com/NewsAndMedia/Resources/2022-Fact-Sheet.pdf
  • 15sartcorsonline.com/AboutSARTCORS
  • 23sartcorsonline.com/ReportSelector
  • 30sartcorsonline.com/Search?&searchType=1&showType=1&results=1&diagnosis=Oocyte%20Donation%20-%20donor%20eggs
  • 32sartcorsonline.com/Search?&searchType=1&showType=1&results=1
  • 38sartcorsonline.com/Search/Results?%2FsearchType=1
  • 49sartcorsonline.com/NewsAndMedia/Resources/2022-Embryo-Transfer-Fact-Sheet.pdf
eim.ieo.iteim.ieo.it
  • 11eim.ieo.it/
  • 12eim.ieo.it/eim-report/
eshre.eueshre.eu
  • 13eshre.eu/Guidelines/Good-practice-guidance
  • 96eshre.eu/Home/Guidelines/ESHRE-Guidelines
  • 113eshre.eu/Guidelines/Clinical-Practice-Guidelines
hfea.gov.ukhfea.gov.uk
  • 14hfea.gov.uk/media/3t4n4v4b/hfea-annual-report-2021-22.pdf
  • 17hfea.gov.uk/about-us/research-statistics/
  • 18hfea.gov.uk/media/3j4n0l2x/hfea-statistics-2019.pdf
  • 19hfea.gov.uk/media/2c2z4u2o/hfea-statistics-2020.pdf
  • 20hfea.gov.uk/media/5p3v0v4a/hfea-statistics-2021.pdf
  • 21hfea.gov.uk/media/8w2p5v2m/hfea-statistics-2022.pdf
  • 22hfea.gov.uk/media/9x7s1v2y/hfea-statistics-2023.pdf
  • 24hfea.gov.uk/about-us/research-statistics/hfea-fertility-data/
  • 25hfea.gov.uk/about-us/research-statistics/fertility-statistics/
  • 26hfea.gov.uk/about-us/inspection-regulation-and-standards/
  • 27hfea.gov.uk/media/2bth2k5y/annual-report-2020-21.pdf
  • 28hfea.gov.uk/media/3n2xqv2r/hfea-annual-report-2022-23.pdf
  • 69hfea.gov.uk/media/2r2m0d2m/hfea-annual-report-2019-20.pdf
  • 85hfea.gov.uk/about-us/news-press-releases-and-consultations/donor-information-and-tracing/
asrm.orgasrm.org
  • 16asrm.org/news-and-publications/news-and-research/2020/asrm-releases-sart-cors-updates/
  • 29asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/fertility-society-committee-published-guidelines/oocyte_donation_and_the_oocyte_donor.pdf
  • 31asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/fertility-treatment-guidelines/oocyte_donation.pdf
  • 83asrm.org/news-and-publications/human-reproduction-science-and-society/donor-oocyte-ethics-statement/
  • 88asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/genetics-infertility/donor_testing_genetic_screening.pdf
  • 89asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/donor_oocyte_disclosure.pdf
  • 94asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/ethics-committee/evidence-based-guidelines-for-patient-information.pdf
  • 97asrm.org/globalassets/asrm/asrm-content/news-and-publications/ethics-statements/disclosure/donor_oocyte_non_identifying_information.pdf
  • 99asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/donor_screening/summary_of_infectious_disease_testing_for_donor_oocytes.pdf
  • 103asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/elective_single_embryo_transfer.pdf
  • 104asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/genetics-infertility/carrier_screening.pdf
  • 105asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/genetics-infertility/standards_for_genetic_testing.pdf
  • 112asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/oocyte_donation_and_the_oocyte_donor.pdf
  • 115asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/clinical-ethics-guidelines-and-statistics.pdf
  • 117asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/psychosocial_aspects_of_donor_conception.pdf
  • 121asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/blastocyst_culture.pdf
  • 124asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/legal-ethical-contracts.pdf
  • 125asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/donor_testing_genetic_screening.pdf
  • 128asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/oocyte_donation.pdf
  • 129asrm.org/globalassets/asrm/asrm-content/news-and-publications/ethics-statements/donor_oocyte_ethics.pdf
academic.oup.comacademic.oup.com
  • 33academic.oup.com/humupd/article/23/4/429/3094105
  • 36academic.oup.com/humrep/article/28/1/39/2918160
  • 47academic.oup.com/humrep/article/25/10/2501/2919602
cochranelibrary.comcochranelibrary.com
  • 34cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002035.pub2/full
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 35ncbi.nlm.nih.gov/pmc/articles/PMC3173247/
  • 39ncbi.nlm.nih.gov/books/NBK560755/
  • 40ncbi.nlm.nih.gov/books/NBK564324/
  • 41ncbi.nlm.nih.gov/pmc/articles/PMC5952796/
  • 42ncbi.nlm.nih.gov/pmc/articles/PMC6371939/
  • 43ncbi.nlm.nih.gov/pmc/articles/PMC7039377/
  • 44ncbi.nlm.nih.gov/pmc/articles/PMC5338933/
  • 45ncbi.nlm.nih.gov/pmc/articles/PMC5077890/
  • 50ncbi.nlm.nih.gov/books/NBK560197/
  • 51ncbi.nlm.nih.gov/books/NBK560198/
  • 52ncbi.nlm.nih.gov/books/NBK560199/
  • 54ncbi.nlm.nih.gov/books/NBK562263/
  • 55ncbi.nlm.nih.gov/books/NBK560200/
  • 56ncbi.nlm.nih.gov/pmc/articles/PMC6335041/
  • 57ncbi.nlm.nih.gov/pmc/articles/PMC3732098/
  • 60ncbi.nlm.nih.gov/books/NBK560329/
  • 61ncbi.nlm.nih.gov/books/NBK560330/
  • 62ncbi.nlm.nih.gov/pmc/articles/PMC4534001/
  • 63ncbi.nlm.nih.gov/pmc/articles/PMC6192294/
  • 65ncbi.nlm.nih.gov/pmc/articles/PMC3663069/
  • 67ncbi.nlm.nih.gov/pmc/articles/PMC7052051/
  • 70ncbi.nlm.nih.gov/pmc/articles/PMC5636284/
  • 71ncbi.nlm.nih.gov/pmc/articles/PMC4482415/
  • 72ncbi.nlm.nih.gov/pmc/articles/PMC3450946/
  • 73ncbi.nlm.nih.gov/pmc/articles/PMC4891707/
  • 76ncbi.nlm.nih.gov/books/NBK560283/
  • 77ncbi.nlm.nih.gov/books/NBK562276/
  • 80ncbi.nlm.nih.gov/pmc/articles/PMC5077869/
  • 81ncbi.nlm.nih.gov/pmc/articles/PMC3322880/
  • 82ncbi.nlm.nih.gov/pmc/articles/PMC7072051/
  • 106ncbi.nlm.nih.gov/pmc/articles/PMC6071412/
  • 116ncbi.nlm.nih.gov/books/NBK279041/
  • 122ncbi.nlm.nih.gov/pmc/articles/PMC4710614/
sciencedirect.comsciencedirect.com
  • 37sciencedirect.com/science/article/pii/S0090825816303217
  • 46sciencedirect.com/science/article/pii/S1472648318300748
pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
  • 48pubmed.ncbi.nlm.nih.gov/23772529/
rcog.org.ukrcog.org.uk
  • 53rcog.org.uk/globalassets/documents/guidelines/gtg/gtg_art.pdf
fertstert.orgfertstert.org
  • 58fertstert.org/article/S0015-0282(18)32333-1/fulltext
  • 59fertstert.org/article/S0015-0282(16)32925-9/fulltext
  • 64fertstert.org/article/S0015-0282(14)00344-7/fulltext
nejm.orgnejm.org
  • 66nejm.org/doi/full/10.1056/NEJMoa1412184
cdc.govcdc.gov
  • 68cdc.gov/nchs/pressroom/2022/20220112.htm
  • 74cdc.gov/art/artdata/index.html
  • 75cdc.gov/art/reports/2017/national-summary.html
  • 95cdc.gov/std/treatment-guidelines/default.htm
aihw.gov.auaihw.gov.au
  • 78aihw.gov.au/reports/australias-health/infertility-and-assisted-reproductive-treatment
  • 79aihw.gov.au/reports-data/behaviours-melanoma/infertility-and-assisted-reproductive-treatment
legislation.gov.uklegislation.gov.uk
  • 84legislation.gov.uk/ukpga/2008/22/part/6
law.cornell.edulaw.cornell.edu
  • 86law.cornell.edu/wex/assisted_reproduction
fda.govfda.gov
  • 87fda.gov/vaccines-blood-biologics/sperm-blood-and-other-tissues/reproductive-tissue-donors
  • 93fda.gov/regulatory-information/search-fda-guidance-documents/human-cells-tissues-and-cellular-and-tissue-based-products-hctps
  • 107fda.gov/regulatory-information/search-fda-guidance-documents/reproductive-tissue-donor-testing
  • 126fda.gov/regulatory-information/search-fda-guidance-documents/human-cells-tissues-and-cellular-and-tissue-based-products-establishments
riksdagen.seriksdagen.se
  • 90riksdagen.se/en/search/?query=donor+assisted+reproduction+act
laws-lois.justice.gc.calaws-lois.justice.gc.ca
  • 91laws-lois.justice.gc.ca/eng/acts/A-13.4/
gesetze-im-internet.degesetze-im-internet.de
  • 92gesetze-im-internet.de/en-egschg/
  • 100gesetze-im-internet.de/en_schutz_embryonen/
acog.orgacog.org
  • 98acog.org/clinical/clinical-guidance/committee-opinion/articles/2019/10/art-and-assisted-reproduction-technologies
health.gov.ilhealth.gov.il
  • 101health.gov.il/English/Topics/Surrogacy/Pages/default.aspx
psychiatry.orgpsychiatry.org
  • 102psychiatry.org/psychiatrists/practice/clinical-practice-guidelines
ecfr.govecfr.gov
  • 108ecfr.gov/current/title-21/chapter-I/subchapter-A/part-1271
  • 109ecfr.gov/current/title-21/section-1271.75
  • 110ecfr.gov/current/title-21/section-1271.80
  • 111ecfr.gov/current/title-21/section-1271.90
nice.org.uknice.org.uk
  • 114nice.org.uk/guidance/cg156/chapter/Recommendations
sst.dksst.dk
  • 118sst.dk/en/english/health/legislation-and-guidelines/donor-conception
stm.fistm.fi
  • 119stm.fi/en/donor-treatment
boe.esboe.es
  • 120boe.es/buscar/act.php?id=BOE-A-2006-9292
who.intwho.int
  • 123who.int/publications/i/item/9789241544878
health.govt.nzhealth.govt.nz
  • 127health.govt.nz/our-work/life-stages/children/donor-assisted-reproduction